CY1116452T1 - Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης - Google Patents

Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης

Info

Publication number
CY1116452T1
CY1116452T1 CY20151100527T CY151100527T CY1116452T1 CY 1116452 T1 CY1116452 T1 CY 1116452T1 CY 20151100527 T CY20151100527 T CY 20151100527T CY 151100527 T CY151100527 T CY 151100527T CY 1116452 T1 CY1116452 T1 CY 1116452T1
Authority
CY
Cyprus
Prior art keywords
methyl
positive
alloystele
regulators
receptors
Prior art date
Application number
CY20151100527T
Other languages
English (en)
Inventor
Scott D Kuduk
Ronald K Chang
Thomas J Greshock
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of CY1116452T1 publication Critical patent/CY1116452T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

Η παρούσα εφεύρεση κατευθύνεται σε ενώσεις πυρανύλ αρύλ μεθύλ βενζοκιναζολινόνης του τύπου (I) οι οποίες είναι θετικοί αλλοστερικοί ρυθμιστές Μ1 υποδοχέα και είναι χρήσιμες στην θεραπεία ασθενειών στις οποίες ενέχεται ο Μ1 υποδοχέας, όπως ασθένειας Alzheimer, σχιζοφρένειας, διαταραχών πόνου ή ύπνου. Η εφεύρεση επίσης κατευθύνεται σε φαρμακευτικές συνθέσεις που περιλαμβάνουν τις ενώσεις και στην χρήση των ενώσεων και των συνθέσεων στην θεραπεία ασθενειών που προκαλούνται από τον Μ1 υποδοχέα.
CY20151100527T 2009-08-31 2015-06-19 Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης CY1116452T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23845709P 2009-08-31 2009-08-31
EP10812601.2A EP2473048B1 (en) 2009-08-31 2010-08-26 Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators

Publications (1)

Publication Number Publication Date
CY1116452T1 true CY1116452T1 (el) 2017-03-15

Family

ID=43628378

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100527T CY1116452T1 (el) 2009-08-31 2015-06-19 Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης

Country Status (27)

Country Link
US (1) US8846702B2 (el)
EP (2) EP2473048B1 (el)
JP (1) JP5658255B2 (el)
KR (1) KR101651312B1 (el)
CN (1) CN102480964B (el)
AU (1) AU2010286683B9 (el)
BR (1) BR112012003464B8 (el)
CA (1) CA2770480C (el)
CO (1) CO6501188A2 (el)
CY (1) CY1116452T1 (el)
DK (1) DK2473048T3 (el)
ES (1) ES2537979T3 (el)
HK (1) HK1208225A1 (el)
HR (1) HRP20150572T1 (el)
HU (1) HUE026296T2 (el)
IL (1) IL217638A (el)
ME (1) ME02151B (el)
MX (1) MX2012002583A (el)
MY (1) MY160075A (el)
NZ (1) NZ598462A (el)
PL (1) PL2473048T3 (el)
PT (1) PT2473048E (el)
RS (1) RS54051B1 (el)
RU (1) RU2507204C2 (el)
SI (1) SI2473048T1 (el)
WO (1) WO2011025851A1 (el)
ZA (1) ZA201201205B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9199939B2 (en) 2009-12-17 2015-12-01 Merck Sharp & Dohme Corp. Quinoline amide M1 receptor positive allosteric modulators
WO2011159553A1 (en) 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
EP2582676B1 (en) 2010-06-15 2016-12-14 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
EP2588104B1 (en) 2010-07-01 2014-12-10 Merck Sharp & Dohme Corp. Isoindolone m1 receptor positive allosteric modulators
WO2012158473A1 (en) * 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
US9403802B2 (en) 2012-03-02 2016-08-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use therefor
US9777005B2 (en) 2012-11-19 2017-10-03 Takeda Pharmaceutical Company Limited Bicyclic heterocyclic compound containing a substituted pyrrole ring
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
EP3313836B1 (en) * 2015-06-26 2020-11-11 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
ES2750868T3 (es) * 2015-09-10 2020-03-27 Suven Life Sciences Ltd Derivados de fluoroindol como moduladores alostéricos positivos del receptor muscarínico M1
US10548899B2 (en) 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
WO2017151449A1 (en) * 2016-03-04 2017-09-08 Merck Sharp & Dohme Corp. M1 receptor positive allosteric modulator compounds and methods of use thereof
WO2018194181A1 (en) * 2017-04-18 2018-10-25 Takeda Pharmaceutical Company Limited Heterocyclic compounds useful as modulators of acetylcholine receptors
KR20210068025A (ko) 2018-09-28 2021-06-08 다케다 야쿠힌 고교 가부시키가이샤 헤테로시클릭 화합물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003A (en) * 1851-03-25 Improvement in scythe-tastenings
RU2167877C2 (ru) 1995-05-31 2001-05-27 Эйсай Ко., Лтд. Производные конденсированных полициклических гетероциклических соединений и способ их получения
CZ304203B6 (cs) 1999-04-30 2014-01-02 Pfizer Products Inc. Modulátor glukokortikoidního receptoru a léčivo pro léčbu zánětlivé choroby s jeho obsahem
WO2001087845A2 (en) * 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
US20060233843A1 (en) 2003-02-19 2006-10-19 Conn P J Treatment of psychosis with a muscarinic m1 receptor ectopic activator
CA2655787A1 (en) * 2006-06-28 2008-01-03 Merck And Co., Inc. Benzyl-substituted quinolone m1 receptor positive allosteric modulators
ES2400695T3 (es) * 2006-07-17 2013-04-11 Amgen Inc. Derivados de quinazolina y piridopirimidina como inhibidores de la cinasa p38
CN104211684A (zh) 2007-09-26 2014-12-17 细胞基因公司 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法
CN102292323B (zh) * 2008-11-20 2014-12-24 默沙东公司 芳基甲基苯并喹唑啉酮 m1受体正向变构调节剂
EP2398324B1 (en) * 2009-02-23 2014-09-03 Merck Sharp & Dohme Corp. PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8293744B2 (en) 2009-04-20 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline M1 receptor positive allosteric modulators
EP2483275B1 (en) 2009-10-01 2014-10-15 Merck Sharp & Dohme Corp. HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
EP2490692B1 (en) 2009-10-21 2016-11-16 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone m1 receptor positive allosteric modulators
EP2512245B1 (en) 2009-12-14 2014-07-23 Merck Sharp & Dohme Corp. Pyridoquinazolinone m1 receptor positive allosteric modulators
GB0921949D0 (en) 2009-12-16 2010-02-03 Fujifilm Mfg Europe Bv Curable compositions and membranes
US8507494B2 (en) 2010-04-30 2013-08-13 Merck Sharp & Dohme Corp. Heterocyclic quinolizine derived M1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
PL2473048T3 (pl) 2015-08-31
RS54051B1 (en) 2015-10-30
EP2473048B1 (en) 2015-03-25
IL217638A (en) 2016-08-31
BR112012003464B1 (pt) 2020-09-01
HUE026296T2 (en) 2016-06-28
CO6501188A2 (es) 2012-08-15
RU2012112064A (ru) 2013-10-10
JP2013503177A (ja) 2013-01-31
MX2012002583A (es) 2012-04-02
MY160075A (en) 2017-02-15
KR101651312B1 (ko) 2016-08-25
BR112012003464A2 (pt) 2015-09-08
BR112012003464B8 (pt) 2021-05-25
KR20120073211A (ko) 2012-07-04
ME02151B (me) 2015-10-20
DK2473048T3 (en) 2015-06-29
AU2010286683B9 (en) 2014-09-04
NZ598462A (en) 2012-12-21
WO2011025851A1 (en) 2011-03-03
US8846702B2 (en) 2014-09-30
AU2010286683B2 (en) 2014-08-07
PT2473048E (pt) 2015-07-02
HK1208225A1 (en) 2016-02-26
CN102480964A (zh) 2012-05-30
CA2770480A1 (en) 2011-03-03
ES2537979T3 (es) 2015-06-16
US20120157438A1 (en) 2012-06-21
EP2473048A4 (en) 2013-02-13
EP2473048A1 (en) 2012-07-11
SI2473048T1 (sl) 2015-06-30
CN102480964B (zh) 2015-07-08
EP2915812A1 (en) 2015-09-09
RU2507204C2 (ru) 2014-02-20
AU2010286683A1 (en) 2012-03-08
ZA201201205B (en) 2013-04-24
CA2770480C (en) 2014-11-18
JP5658255B2 (ja) 2015-01-21
HRP20150572T1 (en) 2015-07-03

Similar Documents

Publication Publication Date Title
CY1117726T1 (el) Θετικοι αλλοστερικοι ρυθμιστες υποδοχεα μ1 κινολιναμιδιου
CY1116452T1 (el) Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης
CY1113665T1 (el) Θετικοι αλλοστερικοι ρυθμιστες του υποδοχεα μ1 με αρυλομεθυλο βενζοκιναζολινονη
CY1120172T1 (el) Αναστολεις κινασων σερινης/θρεονινης
CY1122610T1 (el) Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης
CY1120258T1 (el) Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος
CY1120073T1 (el) Παραγωγα πυραζολο-αμινοπυριμιδινης ως ρυθμιστες της lrrk2
CY1117776T1 (el) Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες
CY1120881T1 (el) Ανταγωνιστες υποδοχεα 5-ητ3
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων
CY1118362T1 (el) Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
CY1116405T1 (el) Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης
CY1116902T1 (el) Παραγωγα ισοξαζολο-πυριδινης
CY1114718T1 (el) ΠΑΡΑΓΩΓΑ 1,2,4-ΤΡΙΑΖΟΛΟ[4,3-a]ΠΥΡΙΔΙΝΗΣ ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ Ή ΤΗΝ ΠΡΟΛΗΨΗ ΝΕΥΡΟΛΟΓΙΚΩΝ ΚΑΙ ΨΥΧΙΑΤΡΙΚΩΝ ΔΙΑΤΑΡΑΧΩΝ
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
CY1126109T1 (el) Αναστολεις toy trpc6
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
CY1115826T1 (el) Μεσα για τη θεραπεια διαταραχων οι οποιες εμπλεκουν τη ρυθμιση των υποδοχεων ρυανοδινης
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
CY1110190T1 (el) Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
EA201691160A1 (ru) Антагонисты s1p3
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren